SBI Life Insurance Company Ltd (SBILIFE) Q1 FY27 Results Analysis: PAT Jumps 22%, Expense Ratio Deteriorates 203 bps

CompoundingAI Research Updated July 24, 2026 2 min read
Positive

SBI Life Insurance Company Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 21,289.65 Cr (+19.51% YoY) and PAT growth of +21.97% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 24, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 21,289.65 Cr (+19.51% YoY)
PAT (Q1)Rs. 724.93 Cr (+21.97% YoY)
EPS (Q1)Rs. 7.23
Market capRs. 186,541.59 Cr
CMPRs. 1,858.60

Quarter Snapshot

SBILIFE delivered strong 19.5% GWP growth and 22% PAT growth, driven by a 40% surge in First Year Premium. However, expense management ratio deteriorated by 203 bps due to a near-doubling of other operating expenses, and 13th-month persistency declined sequentially. Solvency remains strong at 1.96x and embedded value grew to Rs.85,290 crore. The cost trajectory and persistency are key watch items for the FY27 VNB margin guidance of 26-28%.

Key Investment Insights

Key Positives

  • Gross written premium grew 19.51% YoY to Rs.21,289.65 crore.
  • First Year Premium surged 39.99% YoY to Rs.4,954.93 crore.
  • Shareholders' PAT increased 21.97% YoY to Rs.724.93 crore.
  • Embedded value grew to Rs.85,290 crore from Rs.80,790 crore in March 2026.
  • Solvency ratio improved to 1.96x from 1.90x, well above regulatory minimum.
  • Value of New Business stood at Rs.1,410 crore in Q1.

Risk Factors

  • Expenses of Management grew 33.93% YoY, outpacing GWP growth, leading to EoM ratio deterioration of ~203 bps.
  • Other operating expenses nearly doubled (+99.26% YoY) to Rs.836.83 crore.
  • 13th-month persistency declined to 84.35% from 87.89% in Q4FY26.
  • Investment yields on policyholders' funds (without unrealised gains) declined to 6.29% from 8.73% a year ago.
Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.

Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings

Login Now